“treatment resistant depression”的搜索结果，显示 101-110 项，共有 7682 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.

2. Mayo Clinic Physician Update - December 2024

   Page 1.

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma. Rochester, Minn. The purpose of this study is to ...

5. 血液科- 临床试验- 妙佑医疗国际

   Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma. Rochester, Minn. The purpose of this study is to ...

6. 血液科- 临床试验- 妙佑医疗国际

   Ascorbic Acid And Chemotherapy For The Treatment Of Relapsed Or Refractory Lymphoma, CCUS, And Chronic Myelomonocytic Leukemia ... Resistant To Current Standard ...

7. 血液科- 临床试验- 妙佑医疗国际

   ... Resistant To Current Standard Of Care Treatments. Rochester, Minn. This study ... treatment of a blood cancer called multiple myeloma. Linvoseltamab has ...

8. 血液科- 临床试验- 妙佑医疗国际

   Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma. Rochester, Minn. The purpose of this study is to ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... resistant chronic lymphocytic leukemia. Patients ... treatment in patients with treatment-naive ALK-positive advanced NSCLC. ... A Registry for Children Treated ...

10. 血液科- 临床试验- 妙佑医疗国际

    Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma. Rochester, Minn. The purpose of this study is to ...